|
A Competitive Analysis of the Global Asthma and COPD Therapeutics Market …
MarketWatch oBenralizumab, a monoclonal antibody jointly being developed by MedImmune and AstraZeneca in Phase 3 trials. Benralizumab is bound to the interleukin-5 receptor (IL-5R?) and is being evaluated to help asthma control and reduce the onset of asthmatic … |
View full post on asthma – Google News